Inclisiran a better drug in treating familial hypercholesterolemia

Published On 2022-02-02 13:59 GMT   |   Update On 2022-02-02 13:59 GMT
Advertisement

Familial hypercholesterolemia approximately affects 1 in 200 to 1 in 250 people in most countries and is thought to be the most common inherited condition affecting the heart and blood vessels. It is a serious cause of heart attack worldwide and causing a serious threat in global health management.

The ORION- 4 trial in the Journal of the American College of Cardiology reveals that pooled safety and efficacy data of inclisiran, when given twice yearly in addition to maximally tolerated statin therapy with or without other LDL-Cholesterol lowering agents, is an effective, safe, and well-tolerated treatment to lower LDL-Cholesterol in adults with heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease, or atherosclerotic cardiovascular disease risk equivalents.

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News